Phaseline

Companies › Bayer

Bayer: clinical trials, targets and expected readouts

22 active drug programs in 132 registered trials: 64 Phase 2, 32 Phase 3, 24 Phase 1, 12 Phase 4; Oncology, Cardiovascular, Other, Genitourinary; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Radium-223 dichloride (Xofigo, BAY88-8223)
Radium-223 is a radioactive alpha emitter that is taken up by bones and delivers localized
–Phase 4Metastatic Castrate Resistant Prostate Cancer (mCRPC)Nov 2026
Darolutamide
Androgen Receptor antagonist
ARPhase 4Non-metastatic Castration-resistant Prostate Cancer; Biochemically Recurrent Prostate Cancer; Cancer; High-risk Localized Prostate Cancer …Jul 2027
Elinzanetant (BAY3427080)
Neurokinin 1 receptor antagonist; Neurokinin 3 receptor antagonist
TACR1, TACR3Phase 3Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer; Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women; Menopause-related Hot FlashesFeb 2027
Finerenone (BAY94)
Mineralocorticoid receptor antagonist
NR3C2Phase 3Chronic Kidney Disease; Left Ventricular Systolic Dysfunction; Primary Membranous Nephropathy; Heart Failure …Apr 2027
BAY 2927088 (Sevabertinib)
MATE1 and MATE2-K transporter inhibitor
ERBB2, SLC47A1, SLC47A2Phase 3Advanced Non-small Cell Lung Cancer, HER2 Mutation; Advanced Solid Tumors; Healthy ParticipantsOct 2027
Riociguat
Soluble guanylate cyclase positive allosteric modulator
GUCY1B1, GUCY1A2, GUCY1A1Phase 3Hypertension, Pulmonary; Chronic Thromboembolic Pulmonary Hypertension; Pulmonary Arterial HypertensionMay 2028
Aficamten (BAY3723113, CK-3773274)
Cardiac myosin inhibitor
MYH7Phase 3Obstructive Hypertrophic CardiomyopathyMay 2028
BAY 3401016
Semaphorin 3A (Sema3A) antagonist monoclonal antibody
SEMA3APhase 2Alport SyndromeNov 2027
Regorafenib (BAY73)
Tyrosine-protein kinase ABL inhibitor; Serine/threonine-protein kinase RAF inhibitor; Stem cell growth factor receptor inhibitor
ABL1, RAF1, KIT, FGFR1, MAPK11Phase 2Solid Malignant Tumors; Metastatic Colorectal Cancer (mCRC); Colorectal Cancer Liver Metastases; Colorectal Cancer Metastatic …Apr 2028
BAY 3670549–Phase 2Atrial FibrillationMay 2030
BAY3389934
Factor IIa (thrombin) and Factor Xa inhibitor
F2, F10Phase 1Sepsis; Drug-drug InteractionDec 2026
BAY2965501
T-cell co-stimulatory agonist; blocks an enzyme in T-cells to activate them
–Phase 1Advanced Solid TumorsApr 2027
BAY3498264
SOS1 inhibitor
SOS1Phase 1Advanced Solid Tumors Harboring KRAS G12C MutationApr 2027
BAY3375968 (Lanerkitug)
Anti-CCR8 antibody
CCR8Phase 1Advanced Solid TumorsApr 2027
Actinium-225-macropa-pelgifatamab (BAY3546828)
Alpha-emitting radiopharmaceutical targeting GPRC5D; actinium-225 chelated by macropa conj
GPRC5DPhase 1Metastatic Castration-resistant Prostate CancerJun 2027
225Ac-PSMA-Trillium (BAY3563254)
PSMA-targeting alpha-emitting radioligand (actinium-225)
PSMAPhase 1Advanced Metastatic Castration-resistant Prostate CancerNov 2028
BAY2927088 (sevabertinib)
Tyrosine kinase inhibitor targeting mutated EGFR and HER2
EGFR, HER2Phase 1Advanced Non-small Cell Lung CancerDec 2028
BAY 3713372
PRMT5 inhibitor
PRMT5Phase 1MTAP-deleted Solid TumorsJun 2029
BAY 3771249
KRAS G12D inhibitor
KRASPhase 1Advanced/Metastatic Colorectal AdenocarcinomaJul 2029
BAY 3547926
anti-GPC3 antibody-drug conjugate with actinium-225 alpha emitter
GPC3Phase 1Hepatocellular CarcinomaJul 2029
Larotrectinib (BAY2757556)
Neurotrophic tyrosine kinase receptor inhibitor
NTRK1, NTRK2, NTRK3Phase 1Solid Tumors Harboring NTRK Fusion; Advanced Malignant Solid Neoplasm; Advanced Lymphoma; Central Nervous System Neoplasm …–
Nurandociguat (BAY3283142) new tablet
solute carrier family 22 member 8 (SLC22A8) activator
–Phase 1Chronic Kidney Disease–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02637687Larotrectinib (BAY2757556)Phase 1Solid Tumors Harboring NTRK FusionOncologyJul 2024
NCT03829462Regorafenib (BAY73)Phase 3Metastatic Colorectal Cancer (mCRC)OncologySep 2024
NCT03213704Larotrectinib (BAY2757556)Phase 2Advanced Malignant Solid NeoplasmOncologySep 2024
NCT03385655DarolutamidePhase 2Prostate CancerOncologyOct 2024
NCT04803877Regorafenib (BAY73)Phase 2OsteosarcomaOncologyNov 2025
NCT03899428Regorafenib (BAY73)Phase 2Hepatocellular CarcinomaOncologyDec 2025
NCT04062565RiociguatPhase 3Pulmonary Arterial HypertensionCardiovascularDec 2025
NCT04319783DarolutamidePhase 2Advanced Prostate CarcinomaOncologyJun 2026
NCT06631521DarolutamidePhase 1Prostate CAOncologyJun 2026
NCT05057052Regorafenib (BAY73)Phase 2Liver MetastasesOncologySep 2026
NCT07753252BAY 2927088 (Sevabertinib)Phase 1Healthy ParticipantsOtherOct 2026
NCT07722585Nurandociguat (BAY3283142) new tabletPhase 1Chronic Kidney DiseaseGenitourinaryOct 2026
NCT06573411Finerenone (BAY94)Phase 4Primary Membranous NephropathyGenitourinaryOct 2026
NCT07351864Finerenone (BAY94)Phase 4Heart FailureCardiovascularOct 2026
NCT05050084DarolutamidePhase 3Prostate AdenocarcinomaOncologyNov 2026
NCT06173362DarolutamidePhase 2Advanced Prostate AdenocarcinomaOncologyNov 2026
NCT05622136Regorafenib (BAY73)Phase 2Liver CancerOncologyNov 2026
NCT05644379Regorafenib (BAY73)Phase 1Advanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic TherapyOncologyNov 2026
NCT04597125Radium-223 dichloride (Xofigo, BAY88-8223)Phase 4Metastatic Castrate Resistant Prostate Cancer (mCRPC)OncologyNov 2026
NCT05669664DarolutamidePhase 2Locally Advanced Salivary Gland CarcinomaOncologyNov 2026
NCT05672316Regorafenib (BAY73)Phase 1Advanced Colorectal AdenocarcinomaOncologyDec 2026
NCT06627530DarolutamidePhase 4Prostate CancerOncologyDec 2026
NCT05676203DarolutamidePhase 3Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)OncologyDec 2026
NCT05346848DarolutamidePhase 2Prostate CancerOncologyDec 2026
NCT05370807Regorafenib (BAY73)Phase 2Melanoma Stage IIIOncologyDec 2026
NCT05370807Regorafenib (BAY73)Phase 2Melanoma Stage IIIOncologyDec 2026
NCT04781192Regorafenib (BAY73)Phase 1Advanced Biliary Tract CancerOncologyDec 2026
NCT06854640BAY3389934Phase 1SepsisHematologyDec 2026
NCT05917431Regorafenib (BAY73)Phase 2Unresectable Hepatocellular CarcinomaOncologyDec 2026
NCT07026539Finerenone (BAY94)Phase 4Type 2 Diabetes Mellitus (T2DM)GenitourinaryDec 2026
NCT06727409Finerenone (BAY94)Phase 4Patients With Type 2 DiabetesMetabolic and endocrineDec 2026
NCT07501351Regorafenib (BAY73)Phase 2Hepatocellulcar CarcinomaOncologyDec 2026
NCT06099821Regorafenib (BAY73)Phase 2Digestive System CancersOncologyDec 2026
NCT04503694Regorafenib (BAY73)Phase 2Rectal Cancer Stage IIOncologyDec 2026
NCT05366816Regorafenib (BAY73)Phase 2Gastrointestinal Stromal TumorsOncologyDec 2026
NCT06390852Larotrectinib (BAY2757556)Phase 2Advanced LymphomaOncologyDec 2026
NCT06363006Regorafenib (BAY73)Phase 1Hepatocellular CarcinomaOncologyJan 2027
NCT06715280RiociguatPhase 4Chronic Thromboembolic Pulmonary HypertensionCardiovascularJan 2027
NCT05116475DarolutamidePhase 3Prostate CancerOncologyFeb 2027
NCT05113368Regorafenib (BAY73)Phase 2Ovarian CancerOncologyFeb 2027
NCT04757363Regorafenib (BAY73)Phase 2Esophagogastric CancerOncologyFeb 2027
NCT07762287Elinzanetant (BAY3427080)Phase 1Vasomotor Symptoms as a Sex Hormone-dependent Disorder in WomenGenitourinaryFeb 2027
NCT07652723BAY3389934Phase 1Drug-drug InteractionOtherMar 2027
NCT06059664Finerenone (BAY94)Phase 2Kidney Transplant; ComplicationsCardiovascularMar 2027
NCT05794971Regorafenib (BAY73)Phase 3Colorectal Cancer Liver MetastasesOncologyMar 2027
NCT06280105Regorafenib (BAY73)Phase 2Hepatocellular CarcinomaOncologyMar 2027
NCT05196035Finerenone (BAY94)Phase 3Chronic Kidney DiseaseGenitourinaryApr 2027
NCT05614102BAY2965501Phase 1Advanced Solid TumorsOncologyApr 2027
NCT07213570Regorafenib (BAY73)Phase 2Colorectal Cancer MetastaticOncologyApr 2027
NCT05830084Regorafenib (BAY73)Phase 1Ewing SarcomaOncologyApr 2027
NCT06659341BAY3498264Phase 1Advanced Solid Tumors Harboring KRAS G12C MutationOncologyApr 2027
NCT06930118Regorafenib (BAY73)Phase 2Advanced Colorectal Cancer in the Third-line Treatment and BeyondOncologyApr 2027
NCT05537740BAY3375968 (Lanerkitug)Phase 1Advanced Solid TumorsOncologyApr 2027
NCT07071961Regorafenib (BAY73)Phase 2Colorectal CancerOncologyMay 2027
NCT05762536DarolutamidePhase 2Metastatic Castration-resistant Prostate CancerOncologyMay 2027
NCT07040228Regorafenib (BAY73)Phase 1Pancreatic Cancer MetastaticOncologyMay 2027
NCT07559864Regorafenib (BAY73)Phase 2GIST - Gastrointestinal Stromal TumorOncologyJun 2027
NCT06052306Actinium-225-macropa-pelgifatamab (BAY3546828)Phase 1Metastatic Castration-resistant Prostate CancerOncologyJun 2027
NCT07617272DarolutamidePhase 2Prostate Cancer (Adenocarcinoma)OncologyJun 2027
NCT03834961Larotrectinib (BAY2757556)Phase 2Central Nervous System NeoplasmOncologyJul 2027

The 60 nearest readouts of 132 trials; the rest in the app.

From the company's SEC filings

Complete response letters from FDA

Targets

MYH7 (1) NR3C2 (1) TACR1 (1) TACR3 (1) AR (1) KRAS (1) PRMT5 (1) ABL1 (1) RAF1 (1) KIT (1) FGFR1 (1) MAPK11 (1)

Companies with the same targets

Astellas Revolution Medicines Novartis Roche Bristol-Myers Squibb Johnson & Johnson (Janssen) Jiangsu HengRui Medicine TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Quanta Therapeutics Eli Lilly

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.